

# Die Bisphosphonat assoziierte Osteonekrose der Kiefer

Ch. Walter, B. Al-Nawas

Dental Tribune German/ Austrian/Swiss Edition 4-2013

---

## Literatur

1. Marx, R. and D. Stern, *Oral and Maxillofacial Pathology. A Rational for Diagnosis and Treatment*. 2002, Chicago: Quintessence.
2. Marx, R.E., *Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic*. J Oral Maxillofac Surg, 2003. **61**(9): p. 1115-1117.
3. Tarassoff, P. and K. Csermak, *Avascular necrosis of the jaws: risk factors in metastatic cancer patients*. J Oral Maxillofac Surg, 2003. **61**(10): p. 1238-9.
4. Ruggiero, S.L., et al., *Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases*. J Oral Maxillofac Surg, 2004. **62**(5): p. 527-34.
5. Wang, J., N.M. Goodger, and M.A. Pogrel, *Osteonecrosis of the jaws associated with cancer chemotherapy*. J Oral Maxillofac Surg, 2003. **61**(9): p. 1104-7.
6. Pogrel, M.A., *Bisphosphonates and bone necrosis*. J Oral Maxillofac Surg, 2004. **62**(3): p. 391-2.
7. Kuhl, S., et al., *Bisphosphonate-related osteonecrosis of the jaws--a review*. Oral Oncol. **48**(10): p. 938-47.
8. Grötz, K.A., J.U. Piesold, and B. Al-Nawas, *AWMF Leitlinie Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen*. AWMF, 2012.
9. Ruggiero, S.L., et al., *American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update*. J Oral Maxillofac Surg, 2009. **67**(5 Suppl): p. 2-12.
10. Grötz, K.A., et al., *[Relevance of bisphosphonate long-term therapy in radiation therapy of endosteal jaw metastases.]*. Strahlenther Onkol, 2007. **183**(4): p. 190-4.
11. Hansen, T., et al., *Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis--a paradoxical observation?* Virchows Arch, 2006. **449**(4): p. 448-54.
12. Allen, M.R. and D.B. Burr, *The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data*. J Oral Maxillofac Surg, 2009. **67**(5 Suppl): p. 61-70.
13. Walter, C., et al., *Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells*. Clin Oral Investig, 2010. **14**(1): p. 35-41.
14. Ziebart, T., et al., *Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro*. Clin Oral Investig, 2011. **15**(1): p. 105-11.
15. Pabst, A.M., et al., *The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study*. Clin Oral Investig, 2012. **16**(1): p. 87-93.
16. Henry, D.H., et al., *Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma*. J Clin Oncol, 2011. **29**(9): p. 1125-32.
17. Guarneri, V., et al., *Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer*. Breast Cancer Res Treat, 2010. **122**(1): p. 181-8.
18. Koch, F.P., et al., *Osteonecrosis of the jaw related to sunitinib*. Oral Maxillofac Surg, 2011. **15**(1): p. 63-6.

19. Walter, C., et al., *Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients*. *Head Face Med*, 2011. **6**: p. 11.
20. Marx, R.E., J.E. Cillo, Jr., and J.J. Ulloa, *Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment*. *J Oral Maxillofac Surg*, 2007. **65**(12): p. 2397-410.
21. Walter, C., et al., *Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate*. *Eur Urol*, 2008. **54**(5): p. 1066-72.
22. Dimopoulos, M.A., et al., *Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid*. *Ann Oncol*, 2009. **20**(1): p. 117-20.
23. Ripamonti, C.I., et al., *Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan*. *Ann Oncol*, 2009. **20**(1): p. 137-145.
24. Montefusco, V., et al., *Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates*. *Leuk Lymphoma*, 2008. **49**(11): p. 2156-62.
25. Saia, G., et al., *Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction*. *J Oral Maxillofac Surg*, 2010. **68**(4): p. 797-804.
26. Walter, C. and B. Al-Nawas, *Implantation bei Patienten unter oraler Bisphosphonattherapie*. *wissen kompakt*, 2012. **6**: p. 43-52.
27. Grötz, K.A., et al., *Bei welchen Bisphosphonat-Patienten darf ich eigentlich implantieren? Ein systematisches Review*. *Z Zahnarztl Impl*, 2010. **26**(2): p. 153-161.
28. Shirota, T., et al., *Bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla: report of a case*. *Clin Oral Implants Res*, 2009.
29. Walter, C., B. Al-Nawas, and W. Wagner, *The Implications of Bisphosphonate Therapy for Dental Implant Therapy*. *Forum Implantologicum*, 2012. **8**(2): p. 95-100.
30. Chadha, G.K., et al., *Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: A systematic review*. *J Oral Implantol*.